open access
Systemic treatments for advanced cutaneous melanoma — Cochrane Systematic Review 2018


- Uniwersytet Medyczny w Łodzi; Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi
open access
Abstract
Abstract
Keywords
Cochrane meta-analysis; metastatic melanoma; anti-BRAF/anti-MEK therapy; immunotherapy


Title
Systemic treatments for advanced cutaneous melanoma — Cochrane Systematic Review 2018
Journal
Issue
Article type
Review paper
Pages
241-248
Published online
2019-02-15
Page views
1507
Article views/downloads
577
DOI
10.5603/OCP.2018.0030
Bibliographic record
Oncol Clin Pract 2018;14(5):241-248.
Keywords
Cochrane meta-analysis
metastatic melanoma
anti-BRAF/anti-MEK therapy
immunotherapy
Authors
Joanna Połowinczak-Przybyłek
Piotr Potemski


- Polski Instytut Evidence Based Medicine. http://ebm.org.pl/show.php?aid=15739&_tc=272C56A7C6FEB3D89BA5503840A57516 (dostęp z dnia 22.07.2018.).
- http://poland.cochrane.org/pl/jak-interpretować-przeglądy-systematyczne (dostęp z dnia 22.07.2018.).
- Bała M, Leśniak W, Jaeschke R. Proces przygotowywania przeglądów systematycznych, z uwzględnieniem przeglądów Cochrane. Polish Archives of Internal Medicine. 2015; 125(Special Issue): 16–25.
- Leśniak W, Bała M, Jaeschke R, et al. Od danych naukowych do praktycznych zaleceń – tworzenie wytycznych według metodologii GRADE. Polish Archives of Internal Medicine. 2015; 125(Special Issue): 26–41.
- https://poland.cochrane.org/pl/cochrane (dostęp z dnia 22.07.2018).
- Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018; 2: CD011123.
- Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26): 2517–2526.
- Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31(5): 616–622.
- Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372(4): 320–330.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1): 23–34.
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358–365.
- McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014; 15(3): 323–332.
- Gupta A, Love S, Schuh A, et al. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Ann Oncol. 2014; 25(5): 968–974.
- Flaherty KT, Robert C, Hersey P, et al. METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2): 107–114.
- Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. The Lancet Oncology. 2013; 14(8): 733–740.
- Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372(1): 30–39.
- Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386(9992): 444–451.
- Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371(20): 1867–1876.
- Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18): 1694–1703.
- Połowinczak-Przybyłek J, Potemski P. Treatment of patients with advanced melanoma harboring the BRAF V600 mutation. Oncol Clin Pract. 2018; 14: 48–52.